PET [89Zr]DFO-starPEG in Solid Tumors

Description

PRIMARY OBJECTIVES:

I. To descriptively report patterns of [89Zr]DFO-starPEG uptake on whole-body PET (Cohorts A & B).

II. To determine the radiation dosimetry following [89Zr]DFO-starPEG administration (Cohort A).

SECONDARY OBJECTIVES:

I. To determine the safety of [89Zr]DFO-starPEG (Cohorts A & B).

EXPLORATORY OBJECTIVES:

I. To study the pharmacokinetics of [89Zr]DFO-starPEG and estimate its half-life (Cohort A).

OUTLINE:

Participants will be assigned to one of 2 cohorts:

* COHORT A: Participants will receive multiple scans over time
* COHORT B: Participants will receive a scan at a single time point

Participants will be followed for adverse events for approximately 1 week after radiotracer administration until the Day 5-9 visit.